Search form

Search form

Alseres Pharmaceuticals' lead molecular-imaging candidate, Altropane, is in two-part Phase III clinical trials to test its diagnostic efficacy in Parkinson's disease patients with tremor, according to the company chairman and CEO's annual letter to stockholders.

Related Summaries

Endocyte has started a randomized Phase II study of EC145, its drug candidate for ovarian cancer. The trial will look into the efficacy and safety of the drug when given to patients with platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin, a standard chemotherapy. The trial also will evaluate the use of its molecular-imaging agent EC20 for identifying patients who likely will benefit from EC145.

Alseres Pharmaceuticals has completed the enrollment for the initial stage of the Phase III POET-2 program for Altropane -- a molecular imaging agent used in the diagnosis of Parkinson's disease. This stage of the program aims to collect Altropane images for training nuclear medicine readers. The company is working with the FDA in finalizing the design of the Phase III registration study, a company official said.

Alseres Pharmaceuticals said enrollment for the initial stage of a Phase III clinical trial of its molecular imaging agent Altropane is expected to be completed early next year. The company is also in talks to form development and commercialization partnerships for its upcoming molecular imaging and regenerative therapy product lines.

Alseres Pharmaceuticals has opened seven clinical-trial sites to test its molecular imaging agent ALTROPANE, the company said in a news release. The diagnostic drug is used with SPECT imaging to distinguish between Parkinsonian syndromes and non-Parkinsonian syndromes. "We continue to be optimistic about the diagnostic value that ALTROPANE may represent to those with undiagnosed tremor," said one of the principal investigators.

Swedish molecular-imaging company Affibody Holding AB saw an increase in revenue in 2007 and reported progress on molecules for molecular imaging. "We focused our resources on our second-generation Affibody molecules and are on track to commence the first clinical study with our lead cancer imaging product ABY-025 in mid-2008," the company's CEO said in a news release.